- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04401709
Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer
A Randomized, Multi-center Phase III Trial of Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine Alone in Curatively Resected Biliary Tract Cancer
This clinical trial is an open-label, multicenter, phase 3 clinical trial to study the efficacy and safety of adjuvant gemcitabine + capecitabine combination treatment in patients with resectable biliary tract cancer according to imaging studies after surgery. All the patients must complete a consent forms before participating in the clinical trial, and the estimated enrollment period is 36 months after IRB approval.
Drug Dose and Schedule:
- Cohort 1: Gemcitabine/Capecitabine, every 4 weeks, total 6 cycles gemcitabine1,000 mg/m2 over 30 min D1, D8, D15 capecitabine 1660 mg/m2, D1-21
- Cohort 2: Capecitabine, everu 3 weeks, total 8 cycles capecitabine 2,500 mg/m2 D1-14
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Study Background & Rationale:adjuvant capecitabine monotherapy following surgery is regarded as standard treatment after phase 3 BILCAP trial, we need further phase 3 clinical trials to evaluate efficacy of doublet combination adjuvant chemotherapy for Biliary Track Cancer after surgery. Since Korea has much higher incidence rate of Biliary Track Cancer compared to western countries, Korea is considered to be a region that can lead large-scale Biliary Track Cancer clinical trials. In this background, we intend to conduct a randomized phase 3 study to compare adjuvant gemcitabine+cisplatin combination therapy with camecitabine monotherapy following curative intent surgical resection in patients with Biliary Track Cancer .
Primary Objective:
- Disease-free survival at 24 months (2-year DFS)
Primary Hypothesis:
Adjuvant gemcitabine and capecitabine combination treatment confers diseae free survival benefit over capecitabine monotherapy after curative intent surgical resection of biliary tract cancer
- Study Design:
This clinical trial is an open-label, multicenter, phase 3 clinical trial to study the efficacy and safety of adjuvant gemcitabine + capecitabine combination treatment in patients with resectable biliary tract cancer according to imaging studies after surgery. All the patients must complete a consent forms before participating in the clinical trial, and the estimated enrollment period is 36 months after IRB approval.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: JoonOh Park, doctor
- Phone Number: 82-2-3410-3459
- Email: joonoh.park@samsung.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Recruiting
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with histologically confirmed adenocarcinoma of biliary tract canacer (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer) after curative intent R0 or R1 surgical resection
- Pathologic disease stage of T2-4, N0-2, M0 after surgery, according to AJCC 8th TNM staging
- Patients who complete resection (R0 or R1 resection) for biliary tract cancer within 12 weeks of the adjuvant chemotherapy
- No distant metastasis
- ECOG performance sstatus score of 0 or 1
- Age 19 years or older
- Adequate bone marrow fuction (neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L and hemoglobin ≥9 g/dL)
- Adequate liver function (total bilirubin < 1.5 fold the upper limit of normal of the study site (ULN), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 x ULN)
- Adequate kidney function (Creatinine < 1.5 x ULN)
- Unresolved systemic active infection (except for chronic viral hepatitis taking antiviral drugs)
- Not receiving other drugs for clinical trials or chemotherapy within 30 days prior to randomization
- A female participant who is not post-menopausal or amenorrhea less than 12 consecutive months without specific reasons is eligible to participate if she is not pregnant, confirmed by serum tests within 7 days before the initiation of chemotherapy
- The participants provide written informed consent for the study.
- No prior chemotherapy for biliary tract cancer
- Participants of childbearing potential must agree to use an adequate method of contraception for the course of the study throught 120 days after the last dose of chemotherapy (oral contraceptives or mechanical contraception such as intrauterine devices or contraceptive barriers and etc). Childbearing potential female is who is not post-menopausal or amenorrhea less than 12 consecutive months without specific reasons
Exclusion Criteria:
- Other histology type than adenocarcinoma (such as HCC-CCC mixed type or neuroendocrine tumor)
- Ampula of vater cancer
- Has known additional malignancy (participants with non-melanoma skin cancer, or carcinoma in situ (e.g. breast carcinoma, prostate cancer) that have undergone potentially curative therapy without recurrence for more than 3 years are not excluded)
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- Has an active infection requiring systemic therapy (bacteria, virus, fungal, etc)
- Has a known history of Human Immunodeficiency Virus (HIV)
- Has an active of hepatitis A or B (patients under anti-B-viral treatment with HBV DNA 1000≤copies/ml is allowed to particiapte).
- Has a history of severe hemorrhage (gastrointestinal or neurologic) within 2 weeks prior randomization
- Is unable to take oral drug due to gastrointestinal obstruction or any other conditions.
- Any history of significant cardiac disease within 3 months prior to randomization including unstable angina, NYHA (The New York Heart Association )III or IV congestive heart failure, myocardiac infarction, or severe uncontrolled arrhythmias
- Pregnant, breast-feeding or pregnancy test positive female patients
Has any contraindications for investigational drug
- History of hypersensitivity to capecitabine or gemcitabine
- Any hypersensitivity to fluorouracil drugs
- Concurrent administration with sorivudine or brivudine
- DPD(dihydro-pyridine dehydrogenase) deficiency
- History of TS-1(tegafur / gimeracil / oteracil) administration
- Galactose intolerance, Lapp lactase deficince, glucose-galactose malabsorption
- Interstitial pneumonia or pulmonary fibrosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gemcitabine/Capecitabine
gemcitabine1,000 mg/m2 over 30 min D1, D8, D15 capecitabine 1660 mg/m2, D1-21
|
gemcitabine 1,000 mg / m2 IV on day 1, 8, and 15 of each cycle Capecitabine 1,660mg / m2 PO twice daily 1 ~ 21 days for 4 weeks
|
Active Comparator: Capecitabine
capecitabine 2,500 mg/m2 D1-14
|
total 8 cycles Capecitabine 1,250 mg / m2 PO twice daily 1 ~ 14 days for 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Two-year disease free survival (DFS)
Time Frame: 24 months later
|
24 months later
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival (OS)
Time Frame: 24 months later
|
24 months later
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Biliary Tract Diseases
- Biliary Tract Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
- Capecitabine
Other Study ID Numbers
- 2020-01-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biliary Tract Cancer
-
Sun Yat-sen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerChina
-
Gyeongsang National University HospitalSamsung Medical Center; Dong-A University; Chung-Ang UniversityTerminatedMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerKorea, Republic of
-
Hospital de Cancer de Barretos - Fundacao Pio XIIUnknown
-
Fudan UniversityRecruitingAdvanced Biliary Tract CancerChina
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Tianjin Medical University Cancer Institute and...RecruitingResectable Biliary Tract CancerChina
-
University of Kansas Medical CenterRecruitingAdvanced Biliary Tract CancerUnited States
-
Peking Union Medical College HospitalShanghai Junshi Bioscience Co., Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Georgetown UniversityIpsenRecruitingAdvanced Biliary Tract CancerUnited States
-
Seoul National University HospitalBeiGeneActive, not recruitingAdvanced Biliary Tract CancerKorea, Republic of
Clinical Trials on Gemcitabine/Capecitabine
-
Rutgers, The State University of New JerseyRecruitingPancreatic CancerUnited States
-
Assiut UniversityNot yet recruiting
-
NCIC Clinical Trials GroupTerminatedLiver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct CancerCanada
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
Dorte NielsenCompletedCholangiocarcinomaDenmark
-
Vejle HospitalCompletedCholangiocarcinomaDenmark
-
Swiss Group for Clinical Cancer ResearchCentral European Cooperative Oncology GroupCompletedPancreatic CancerSwitzerland, Italy, Israel, Austria
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.Recruiting
-
Klinikum der Universitaet Muenchen, GrosshadernLudwig-Maximilians - University of Munich; The European Society for Hyperthermic...Unknown
-
Tianjin Medical University Cancer Institute and...UnknownMetastatic Breast CancerChina